Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion.
Several lines of evidence suggest that ovarian hormones influence glucose homeostasis, although their exact role in humans has not been clearly defined. In the present study, we sought to test the hypothesis that ovarian hormones regulate glucose homeostasis by examining the effect of pharmacologically induced ovarian hormone deficiency on glucose disposal and insulin secretion. Young, healthy women with regular menstrual patterns were studied during the follicular and luteal phases of their cycle at baseline and after 2 mo of treatment with gonadotropin-releasing hormone agonist (GnRHa; n = 7) or placebo (n = 6). Using hyperglycemic clamps, in combination with stable isotope-labeled (i.e., (13)C and (2)H) glucose tracers, we measured glucose disposal and insulin secretion. Additionally, we assessed body composition and regional fat distribution using radiologic imaging techniques as well as glucoregulatory hormones. Ovarian hormone suppression with GnRHa did not alter body composition, abdominal fat distribution, or thigh tissue composition. There was no effect of ovarian suppression on total, oxidative, or nonoxidative glucose disposal expressed relative to plasma insulin level. Similarly, no effect of ovarian hormone deficiency was observed on first- or second-phase insulin secretion or insulin clearance. Finally, ovarian hormone deficiency was associated with an increase in circulating adiponectin levels but no change in leptin concentration. Our findings suggest that a brief period of ovarian hormone deficiency in young, healthy, eugonadal women does not alter glucose disposal index or insulin secretion, supporting the conclusion that ovarian hormones play a minimal role in regulating glucose homeostasis. Our data do, however, support a role for ovarian hormones in the regulation of plasma adiponectin levels.
Toth
Michael J
MJ
Department of Medicine and Obstetrics and Gynecology, University of Vermont, Burlington, VT 05405, USA. michael.toth@uvm.edu
Cooper
Brian C
BC
Pratley
Richard E
RE
Mari
Andrea
A
Matthews
Dwight E
DE
Casson
Peter R
PR
D050153:Abdominal Fat / Q000502:physiology; D015502:Absorptiometry, Photon; D052242:Adiponectin / Q000097:blood; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D001823:Body Composition / Q000502:physiology; D002097:C-Reactive Protein / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D005947:Glucose / Q000378:metabolism*; D015309:Glucose Clamp Technique; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D007700:Kinetics; D020738:Leptin / Q000097:blood; D016729:Leuprolide / Q000494:pharmacology*; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism*; D010101:Oxygen Consumption / Q000502:physiology; D014057:Tomography, X-Ray Computed
C499918:ADIPOQ protein, human; D052242:Adiponectin; D001786:Blood Glucose; D004967:Estrogens; D007328:Insulin; D020738:Leptin; D007987:Gonadotropin-Releasing Hormone; D002097:C-Reactive Protein; D016729:Leuprolide; D005947:Glucose